A novel anti-PcrV antibody providing enhanced protection against Pseudomonas aeruginosa in multiple animal infection models. - Wikidata - awgldk - TriplyDB

A novel anti-PcrV antibody providing enhanced protection against Pseudomonas aeruginosa in multiple animal infection models.

A novel anti-PcrV antibody providing enhanced protection against Pseudomonas aeruginosa in multiple animal infection models.

http://www.wikidata.org/entity/Q30408273

about

Pseudomonas aeruginosa ventilator-associated pneumonia management Protective Efficacy of the Trivalent Pseudomonas aeruginosa Vaccine Candidate PcrV-OprI-Hcp1 in Murine Pneumonia and Burn Models.Synthesis and structure-activity relationships of novel phenoxyacetamide inhibitors of the Pseudomonas aeruginosa type III secretion system (T3SS).High Throughput Combinatorial Formatting of PcrV Nanobodies for Efficient Potency Improvement Genetic engineering of Francisella tularensis LVS for use as a novel live vaccine platform against Pseudomonas aeruginosa infections.Innate Immune Signaling Activated by MDR Bacteria in the Airway Pseudomonas aeruginosa Bacteremic Patients Exhibit Nonprotective Antibody Titers Against Therapeutic Antibody Targets PcrV and Psl Exopolysaccharide.Draft Genome Sequence of a Pseudomonas aeruginosa Strain Able To Decompose N,N-Dimethyl Formamide.Inhibition of Pseudomonas aeruginosa ExsA DNA-Binding Activity by N-Hydroxybenzimidazoles.HigB of Pseudomonas aeruginosa Enhances Killing of Phagocytes by Up-Regulating the Type III Secretion System in Ciprofloxacin Induced Persister Cells.The Innovative Medicines Initiative's New Drugs for Bad Bugs programme: European public-private partnerships for the development of new strategies to tackle antibiotic resistance.Pediatric Multiple Organ Dysfunction Syndrome: Promising Therapies.Considerations and caveats in anti-virulence drug development.A multifunctional bispecific antibody protects against Pseudomonas aeruginosa.Pharmacological Targeting of the Host-Pathogen Interaction: Alternatives to Classical Antibiotics to Combat Drug-Resistant Superbugs.Different drugs for bad bugs: antivirulence strategies in the age of antibiotic resistance.Antimicrobial resistance in the next 30 years, humankind, bugs and drugs: a visionary approach.Impact of Type III Secretion Effectors and of Phenoxyacetamide Inhibitors of Type III Secretion on Abscess Formation in a Mouse Model of Pseudomonas aeruginosa Infection.Nanomedicine and advanced technologies for burns: Preventing infection and facilitating wound healing.Targeting the gram-negative bacteria peptidoglycan synthase MraY as a new approach for monoclonal antibody anti-bacterial activity.PscI is a type III secretion needle anchoring protein with in vitro polymerization capacities.An engineered bispecific DNA-encoded IgG antibody protects against Pseudomonas aeruginosa in a pneumonia challenge model.Exoenzyme T Plays a Pivotal Role in the IFN-γ Production after Pseudomonas Challenge in IL-12 Primed Natural Killer Cells.MEDI3902 correlates of protection against severe Pseudomonas aeruginosa pneumonia in a rabbit acute pneumonia model.Conserved OprF as a Selective Immunogen against Pseudomonas aeruginosa.

P2860

Q26768365-696D0DB8-AD02-4F1E-BC82-DB6235BC8A4A Q33822579-D6875449-1E85-4F86-A884-FBD7700FEFCF Q35118409-2FEB13AB-BF5B-4C9C-95BD-CC1C285D6899 Q36029891-128746DD-2A24-4995-9C33-18F0C5B97B0D Q36147444-32EB5A59-A138-4017-B072-825151426D14 Q36422470-53A4B8D7-33AF-432D-B06A-4C8C2A095797 Q36487854-B4260711-E761-4DC9-BC2A-51B323E8F7FC Q36548180-7411ABB4-F27C-44F2-83DB-E88DC196CF71 Q36571859-FE9DFCC7-70D9-4385-9EE2-31127A8B8364 Q37339442-8403ACBF-61F1-4728-81B8-A08FA99C3839 Q38633668-B84D81E7-48B4-4BC7-A3A1-8214E399050D Q38751931-489C6B7A-3F27-4C5E-A0F3-B8E4873FB18B Q38810589-E9C83AA7-EA4D-4664-AE93-40D25B5FC0F7 Q38940907-A2730B88-571A-4B32-B5B7-785CB3385D5D Q39173330-282499DB-B1DE-475A-9B1E-5460AADD5E7A Q39197564-0B3EC9C8-4DA8-4A57-B3AA-51FDED50CCAF Q39451464-8E4ACD92-B7DE-4115-8BDA-C2264297AA6B Q40093582-7410709A-9030-4660-A7DD-E21DE010CF4D Q40104332-3B892862-3F80-4875-91AA-EBAA31B02E6A Q40176262-4FBD8B2E-AD4C-4586-8CC6-3FE9A6827B68 Q41525965-49CAD640-80E9-45BE-8B06-531F9A800ACB Q41693828-D35DEDD9-0B7F-4A32-ADA6-CB53AA23E2A4 Q42700505-95245C03-1534-461A-B98A-9366E68A0432 Q51747341-A7536393-5A6E-407D-9D80-C8F2CB9A9D00 Q54260241-11072849-9057-4697-AC3B-E31A7572561B

P2860

A novel anti-PcrV antibody providing enhanced protection against Pseudomonas aeruginosa in multiple animal infection models.

http://www.wikidata.org/entity/Q30408273

description

2014 nî lūn-bûn

@nan

2014 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

A novel anti-PcrV antibody pro ...... tiple animal infection models.

@ast

A novel anti-PcrV antibody pro ...... tiple animal infection models.

@en

type

label

A novel anti-PcrV antibody pro ...... tiple animal infection models.

@ast

A novel anti-PcrV antibody pro ...... tiple animal infection models.

@en

prefLabel

A novel anti-PcrV antibody pro ...... tiple animal infection models.

@ast

A novel anti-PcrV antibody pro ...... tiple animal infection models.

@en

P1433

Q30408273-D6443F31-2B04-42BE-8089-3F4E77BFD205

P1476

Q30408273-B8DDF9E8-8A17-41E7-B482-BB56A275FA99

P2093

Q30408273-13770745-5935-4CEB-9CB5-48AC3578A61B

Q30408273-24360BF9-DF2C-47DA-970F-A9917F85F618

Q30408273-29C7F176-F51E-4701-B06A-CE2E64BF808D

Q30408273-2FEC5D0B-AF79-4E0C-9647-94FB7E900BF9

Q30408273-4D9F3EA0-C61A-4E8E-8A62-E85E3153DA89

Q30408273-8CDFA0B1-2F34-41F5-BF3F-B2FAAC63E049

Q30408273-8D1E04B6-7F77-44EF-89B3-44F5DDCDA55E

Q30408273-A77BCC05-0845-4849-AF89-63DE76CD5057

Q30408273-BA03447D-5ACF-4698-9EAE-3F70327A5459

Q30408273-CE45766E-E677-4716-BCCF-47091CB261B3

P2860

Q30408273-0B0924A5-9D52-40F5-9B00-226FF69497CD

Q30408273-0C4D9170-A9BE-4477-983E-511E931802A4

Q30408273-0F4A40CD-1096-4A40-9F36-549A907130ED

Q30408273-12CA951C-232D-428C-B989-C0BDA7829BA1

Q30408273-1522F650-05C0-4E50-949E-AA67CA923ECE

Q30408273-16F801FF-94BF-455B-BF62-21A04785FC36

Q30408273-1708870D-F6FD-4D4B-8B52-D3F74ADD3129

Q30408273-1E6EBDB7-AC1D-42E2-8330-6744F700AC2E

Q30408273-21608DE2-DBD1-42EB-818C-0C2216BDF2FC

Q30408273-33EE42A4-2F16-4FCE-A63A-60B5EE9BEEDF

P304

Q30408273-059D188F-B957-4386-B256-AD9FE8209B9F

P31

Q30408273-4DA362C0-8BC7-4489-8402-764F558426F1

P356

Q30408273-39F77765-BD13-44A6-A349-4B9382C246C6

P407

Q30408273-EA154BDB-50C7-4CED-B5E5-ED9EA3546E54

P433

Q30408273-15AFB1B4-6F85-4E03-8574-C94638F58D26

P478

Q30408273-FDDC21AD-F7A6-42B6-ACF5-315B9DEFCAD0

P577

Q30408273-3970FB35-4C9B-4909-B84C-7701F38C96D0

P5875

Q30408273-5D43F67C-E579-44BA-9114-4927502CDB30

P698

Q30408273-87A962B1-F3CC-4075-9817-3EE7D5839C9D

P921

Q30408273-8C947099-181B-4055-9137-645B66CDCC64

Q30408273-D704070C-D070-4380-AF45-A2C0E74F081E

P932

Q30408273-5E0E6C5E-ABAD-4452-8C93-770EB8743672

P356

P1433

Antimicrobial Agents and Chemotherapy

P1476

A novel anti-PcrV antibody pro ...... tiple animal infection models.

@en

P2093

Antonio DiGiandomenico

http://www.w3.org/2001/XMLSchema#string

Bret Sellman

http://www.w3.org/2001/XMLSchema#string

C Kendall Stover

http://www.w3.org/2001/XMLSchema#string

Jessica C Bonnell

http://www.w3.org/2001/XMLSchema#string

Jingying Zha

http://www.w3.org/2001/XMLSchema#string

Kimberly Cook

http://www.w3.org/2001/XMLSchema#string

Li Peng

http://www.w3.org/2001/XMLSchema#string

Maria Camara

http://www.w3.org/2001/XMLSchema#string

Partha Chowdury

http://www.w3.org/2001/XMLSchema#string

Paul Warrener

http://www.w3.org/2001/XMLSchema#string

P2860

PcrV immunization enhances survival of burned Pseudomonas aeruginosa-infected mice

Effects of monoclonal anti-PcrV antibody on Pseudomonas aeruginosa-induced acute lung injury in a rat model

Monoclonal antibody-based therapies for microbial diseases

Identification of broadly protective human antibodies to Pseudomonas aeruginosa exopolysaccharide Psl by phenotypic screening.

Intranasal immunization with heterologously expressed polysaccharide protects against multiple Pseudomonas aeruginosa infections.

Amino acid residues 196-225 of LcrV represent a plague protective epitope

Role of the type III secreted exoenzymes S, T, and Y in systemic spread of Pseudomonas aeruginosa PAO1 in vivo

Preclinical in vitro and in vivo characterization of the fully human monoclonal IgM antibody KBPA101 specific for Pseudomonas aeruginosa serotype IATS-O11.

Treatment with monoclonal antibodies against Clostridium difficile toxins.

Clinical outcomes of type III Pseudomonas aeruginosa bacteremia.

P304

4384-4391

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1128/AAC.02643-14

http://www.w3.org/2001/XMLSchema#string

P407

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

58

http://www.w3.org/2001/XMLSchema#string

P577

2014-05-19T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

262538556

http://www.w3.org/2001/XMLSchema#string

P698

24841258

http://www.w3.org/2001/XMLSchema#string

P921

Pseudomonas aeruginosa

P932

4136058

http://www.w3.org/2001/XMLSchema#string